drugset / Trial / NCT00972244

Trial to Evaluate the Efficacy and Safety of Dapagliflozin in Japanese Type 2 Diabetes Mellitus Patients

NCT00972244

Phase 2 Completed 417 enrolled AstraZeneca Bristol-Myers Squibb · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to obtain information on efficacy and safety of dapagliflozin in Japanese patients with Type 2 Diabetes. This will be done by comparing the effect of dapagliflozin to placebo when given in oral doses.

Timeline

Start
2009-08
Primary completion
2010-05
Completion
2010-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Dapagliflozin Small molecule 1 mg Oral
Subject Dapagliflozin Small molecule 2.5 mg Oral
Subject Dapagliflozin Small molecule 5 mg Oral
Subject Dapagliflozin Small molecule 10 mg Oral